Northeast Pharmaceutical Group Co., Ltd. (SHE:000597)
China · Delayed Price · Currency is CNY 5.20
+0.05 (0.97%)
Feb 3, 2026, 3:04 PM CST
SHE:000597 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 374.58 | 409.85 | 358.46 | 350.25 | 99.03 | 12.26 |
Depreciation & Amortization | 565.18 | 565.18 | 574.81 | 561.11 | 550.91 | 480.76 |
Other Amortization | 7.74 | 7.74 | 0.27 | 0.36 | 2.29 | 1.94 |
Loss (Gain) From Sale of Assets | -6.19 | -6.19 | -0.17 | -419.3 | -3.29 | -12.29 |
Asset Writedown & Restructuring Costs | 17.83 | 17.83 | 3.9 | 7.97 | 28.96 | 23.17 |
Loss (Gain) From Sale of Investments | -5.16 | -5.16 | -8.61 | - | -54.32 | - |
Provision & Write-off of Bad Debts | -5.45 | -5.45 | -5.62 | 21.92 | 13.14 | 0.66 |
Other Operating Activities | 205.55 | 219.65 | 329.64 | 273.03 | 224.56 | 183.06 |
Change in Accounts Receivable | -82.53 | -82.53 | 149.06 | 115.04 | -268.93 | 249.18 |
Change in Inventory | 57.14 | 57.14 | -150.94 | -5.64 | 8.27 | -35.39 |
Change in Accounts Payable | -528.69 | -528.69 | -747.71 | 151.82 | 160.33 | -387.76 |
Change in Other Net Operating Assets | 22.18 | 22.18 | 102.54 | 59.37 | -1.19 | 53.99 |
Operating Cash Flow | 709.4 | 758.76 | 586.75 | 1,109 | 746.51 | 570.92 |
Operating Cash Flow Growth | 2.93% | 29.32% | -47.07% | 48.50% | 30.75% | 61.92% |
Capital Expenditures | -84.92 | -159.43 | -235.43 | -244.13 | -119.81 | -400.38 |
Sale of Property, Plant & Equipment | 3.5 | 2.7 | 7.47 | 2.67 | 3.83 | 77.71 |
Cash Acquisitions | -127.24 | -127.24 | - | -14.89 | - | - |
Divestitures | - | - | - | - | -0 | - |
Investment in Securities | - | - | - | - | 15.9 | - |
Other Investing Activities | -14 | - | - | - | - | - |
Investing Cash Flow | -222.66 | -283.97 | -227.96 | -256.34 | -100.07 | -322.67 |
Short-Term Debt Issued | - | 6,112 | 5,985 | - | - | - |
Long-Term Debt Issued | - | 1,772 | 2,760 | 3,051 | 3,877 | 3,631 |
Total Debt Issued | 8,451 | 7,884 | 8,745 | 3,051 | 3,877 | 3,631 |
Short-Term Debt Repaid | - | -6,843 | -4,167 | - | - | - |
Long-Term Debt Repaid | - | -2,470 | -2,857 | -3,382 | -4,092 | -4,091 |
Total Debt Repaid | -9,554 | -9,313 | -7,024 | -3,382 | -4,092 | -4,091 |
Net Debt Issued (Repaid) | -1,104 | -1,429 | 1,721 | -331.23 | -215.4 | -460.2 |
Issuance of Common Stock | - | - | - | 234.78 | - | 36 |
Repurchase of Common Stock | - | - | -14.22 | - | -7.36 | - |
Common Dividends Paid | -217.98 | -206.14 | -219.78 | -109.46 | -165.52 | -124.96 |
Other Financing Activities | 621.29 | 481.62 | -1,106 | 146.92 | 255.88 | 189.88 |
Financing Cash Flow | -700.22 | -1,153 | 381.1 | -58.99 | -132.39 | -359.28 |
Foreign Exchange Rate Adjustments | 9.6 | 9.68 | 6.29 | 6.91 | -1.68 | -1.64 |
Net Cash Flow | -203.89 | -668.96 | 746.18 | 800.16 | 512.36 | -112.67 |
Free Cash Flow | 624.48 | 599.34 | 351.32 | 864.44 | 626.7 | 170.54 |
Free Cash Flow Growth | 26.46% | 70.59% | -59.36% | 37.94% | 267.49% | 38.16% |
Free Cash Flow Margin | 9.12% | 7.99% | 4.26% | 9.81% | 7.69% | 2.31% |
Free Cash Flow Per Share | 0.44 | 0.42 | 0.24 | 0.62 | 0.44 | 0.14 |
Cash Income Tax Paid | 415.15 | 491.62 | 535.67 | 418.09 | 414.3 | 389.85 |
Levered Free Cash Flow | -17.65 | -225.43 | 1,661 | 1,193 | 1,324 | 366.64 |
Unlevered Free Cash Flow | 11.88 | -185.1 | 1,709 | 1,251 | 1,399 | 442.18 |
Change in Working Capital | -444.68 | -444.68 | -665.92 | 313.23 | -114.77 | -118.64 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.